These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38546663)

  • 1. Physical Activity Using a Wearable Device as an Alternative to Performance Status in Patients With Advanced Lung Cancer.
    Ito K; Suzuki Y; Sakaguchi T; Fujiwara K; Nishii Y; Yasui H; Taguchi O; Hataji O
    JAMA Oncol; 2024 May; 10(5):648-651. PubMed ID: 38546663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wearable Device-Based Intervention for Promoting Patient Physical Activity After Lung Cancer Surgery: A Nonrandomized Clinical Trial.
    Lee J; Kong S; Shin S; Lee G; Kim HK; Shim YM; Cho J; Kang D; Park HY
    JAMA Netw Open; 2024 Sep; 7(9):e2434180. PubMed ID: 39302678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
    JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of Wearable Physical Activity Monitors in Patients With Cancer.
    Gupta A; Stewart T; Bhulani N; Dong Y; Rahimi Z; Crane K; Rethorst C; Beg MS
    JCO Clin Cancer Inform; 2018 Dec; 2():1-10. PubMed ID: 30652571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actigraphy as an assessment of performance status in patients with advanced lung cancer.
    Fujisawa D; Temel JS; Greer JA; El-Jawahri A; Traeger L; Jacobs JM; Cutrono S; Pirl WF
    Palliat Support Care; 2019 Oct; 17(5):574-578. PubMed ID: 30739635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
    Buccheri G; Ferrigno D; Tamburini M
    Eur J Cancer; 1996 Jun; 32A(7):1135-41. PubMed ID: 8758243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
    Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
    Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia.
    Ruan GT; Xie HL; Yuan KT; Lin SQ; Zhang HY; Liu CA; Shi JY; Ge YZ; Song MM; Hu CL; Zhang XW; Liu XY; Yang M; Wang KH; Zheng X; Chen Y; Hu W; Cong MH; Zhu LC; Deng L; Shi HP
    J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2813-2823. PubMed ID: 37902006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer.
    Ruan GT; Xie HL; Zhang HY; Zhang Q; Deng L; Wang ZW; Zhang X; Ge YZ; Hu CL; Tang M; Song MM; Zhang XW; Liu T; Li XR; Zhang KP; Yang M; Gong YZ; Chen YB; Yu KY; Cong MH; Pan L; Tang WZ; Wang KH; Shi HP
    Clin Nutr; 2022 Oct; 41(10):2284-2294. PubMed ID: 36096062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer.
    Dolan RD; Daly L; Sim WMJ; Fallon M; Ryan A; McMillan DC; Laird BJ
    Clin Nutr; 2020 Sep; 39(9):2889-2895. PubMed ID: 31926762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
    Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
    Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
    Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
    Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different.
    Broderick JM; Hussey J; Kennedy MJ; O' Donnell DM
    J Geriatr Oncol; 2014 Jan; 5(1):49-56. PubMed ID: 24484718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study.
    Collins JT; Noble S; Chester J; Davies HE; Evans WD; Farewell D; Lester JF; Parry D; Pettit R; Byrne A
    Support Care Cancer; 2018 Jan; 26(1):119-127. PubMed ID: 28721555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
    Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
    J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.
    Takahashi M; Takahashi M; Komine K; Yamada H; Kasahara Y; Chikamatsu S; Okita A; Ito S; Ouchi K; Okada Y; Imai H; Saijo K; Shirota H; Takahashi S; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(6):e0179694. PubMed ID: 28640844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
    Kim J; Cho CK; Yoo HS
    Integr Cancer Ther; 2016 Dec; 15(4):467-477. PubMed ID: 27151594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.